Dutasteride Combination Therapy: Minoxidil, PRP and LLLT

Combination therapy using dutasteride with other hair loss treatments is an active area of research. The most studied combination is dutasteride + minoxidil, which targets different mechanisms (hormonal + vasodilation). Combining dutasteride with low-level laser therapy or with platelet-rich plasma (PRP) is also discussed clinically. The published trial evidence for any of these pairings is thin, and a 2026 network meta-analysis of 27 randomized trials found no significant difference between interventions on hair density. Treating hair loss with dutasteride is off-label; the FDA approves it for bph/">benign prostatic hyperplasia only.

Dutasteride + Minoxidil

The most commonly used combination. Dutasteride blocks DHT while minoxidil stimulates growth. In the 2026 network meta-analysis (27 trials, 3,012 participants) the highest-ranked regimens for overall efficacy were minoxidil paired with spironolactone, flutamide or finasteride. The authors caution that the rankings rest on few studies and carry real uncertainty. We could locate no randomized trial of oral dutasteride plus minoxidil against either drug alone. Full combination guide.

Dutasteride + Low-Level Laser Therapy (LLLT)

LLLT devices such as laser caps and combs are sometimes added to dutasteride. We could locate no controlled trial testing that pairing, so any additive benefit is unproven rather than demonstrated.

Dutasteride + PRP

PRP provides growth factors that may stimulate follicle regeneration. In the 2026 network meta-analysis, PRP combined with minoxidil ranked highest for hair count, followed by PRP alone and then dutasteride, again with the authors’ caveat about uncertainty. PRP combined specifically with dutasteride was not among the ranked regimens.

Combination therapy overview · All studies

Sources

  • Bai Y, Ma X, Wei F, et al. Combination therapy in androgenetic alopecia: a network meta-analysis of minoxidil and other pharmacological agents. Aesthetic Plast Surg. 2026;50(13):5415-5426. PubMed 42168420